DelveInsight’s “Connective Tissue Disease associated with Interstitial Lung Disease (CTD-ILD) Market Insights, Epidemiology and Market Forecast – 2032” report delivers an in-depth understanding of the Connective Tissue Disease associated with Interstitial Lung Disease (CTD-ILD), historical and forecasted epidemiology and the Connective Tissue Disease associated with Interstitial Lung Disease (CTD-ILD) market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, Japan, and China.
Key Highlights Connective Tissue Disease associated with Interstitial Lung Disease Market
- Key Companies working in the Connective Tissue Disease associated with the Interstitial Lung Disease market are Roche, AstraZeneca, Novartis, Pfizer and many others.
- Key Therapies in Connective Tissue Disease associated with Interstitial Lung Disease are OFEV (Nintedanib), GSK1550188, GNI-EPS, and many others
- The market size for the Connective Tissue Disease associated with Interstitial Lung Disease market is USD XX Million by 2032
- The CAGR for the Connective Tissue Disease associated with the Interstitial Lung Disease market is XX%
Connective Tissue Disease associated with Interstitial Lung Disease Overview
Connective Tissue Diseases (CTDs) are systemic autoimmune disorders caused by excessive immune-activated inflammation that targets the connective tissues of the body, as seen in rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), Sjogren’s syndrome (SS), idiopathic inflammatory myopathies such as dermatomyositis (DM) and polymyositis (PM), systemic sclerosis (SSc), and mixed connective tissue disease (MCTD). CTDs can cause serious complications for the pulmonary system, including lung bleeding, inflammation, and scarring of the spaces between the lung’s air sacs and the blood vessels. This kind of inflammation and scarring are typical of ILD, and when CTDs cause ILD (CTD-ILD), it can prevent oxygen from being absorbed in the lung and lead to shortness of breath, cough, and fatigue
Connective Tissue Disease associated with Interstitial Lung Disease Epidemiology Insights
- The total prevalent cases of Interstitial Lung Disease (ILD) in the 7MM and China was nearly 5.5 million, of which diagnosed ILD cases were around 4 million.
- China showed the highest diagnosed prevalent population of CTD-ILD compared to other 7MM countries, with nearly 7.7 million cases in 2022. As per DelveInsight’s estimates, the country alone accounts for nearly 73% of total diagnosed prevalent cases, for CTD-ILD, in the 7MM and China, followed by the US, contributing 12% of all the CTD-ILD cases.
- The type-specific distribution of diagnosed prevalent cases of CTD-ILD showed SSc-ILD, RA-ILD, pSS-ILD, SLE-ILD, PM/DM-ILD, and other CTD-ILDs comprised 7%, 22%, 39%, 4%, 4%, and 23% cases, respectively.
Click here to learn more about the Connective Tissue Disease associated with Interstitial Lung Disease Market Landscape
The Report Covers the Connective Tissue Disease associated with Interstitial Lung Disease Epidemiology Segmented by:
- Connective Tissue Disease associated with Interstitial Lung Disease prevalent cases
- Connective Tissue Disease associated with Interstitial Lung Disease incident cases
- Connective Tissue Disease associated with Interstitial Lung Disease treatment cases
- Connective Tissue Disease associated with Interstitial Lung Disease diagnosed cases
Connective Tissue Disease associated with Interstitial Lung Disease Market Outlook
There is currently no feasible treatment option or cure for any CTD-ILD type. Treatment choices in CTD-ILD are affected by the CTD diagnosis and time since diagnosis, the severity of the ILD, the course of the illness, extrapulmonary CTD manifestations, and patient-specific factors. Patients with CTD-ILD commonly receive immunotherapies and medications that slow the development of their illness. Under the brand name OFEV (nintedanib) and ACTEMRA (Tocilizumab), the drugs were approved in 2019 and 2021, respectively, for SSc-ILD and are also used for treating other CTD-ILDs, help in slowing down the declining rate of lung function in adults.The launch of emerging therapies, such as BENLYSTA (GlaxoSmithKline) and ETUARY (Beijing Continent Pharmaceutical Co), are expected to impact the market positively.
- Novartis
- Pfizer
- AstraZeneca
- Roche
And many others
Connective Tissue Disease associated with Interstitial Lung Disease Therapies Covered and Analyzed in the Report
- OFEV (Nintedanib)
- GSK1550188
- GNI-EPS
And many others
Learn more about the Key Companies and Emerging Therapies in the Connective Tissue Disease associated with Interstitial Lung Disease Market
Table of Contents
- Key Insights
- Connective Tissue Disease associated with Interstitial Lung Disease Introduction
- Executive Summary of Connective Tissue Disease associated with Interstitial Lung Disease
- Disease Background and Overview
- Epidemiology and patient population
- Connective Tissue Disease associated with Interstitial Lung Disease Emerging Therapies
- Connective Tissue Disease associated with Interstitial Lung Disease Market Outlook
- Market Access and Reimbursement of Therapies
- Market Drivers
- Market Barriers
- Appendix
- Report Methodology
- DelveInsight Capabilities
- Disclaimer
Learn about the detailed offerings of the report @ Connective Tissue Disease associated with Interstitial Lung Disease Market Outlook
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Adya Kaul
Email: Send Email
Phone: 919650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services